News

Grandner highlights the importance of focusing on insomnia treatment for sleep-related anxiety—not anxiety treatment.

An analysis of data from the LIBERTY AD trial presented at RAD 2024 details the risk of infections observed with dupilumab use with up to 5 years of follow-up.

The new approval expands the treatment area by 4 times the previously approved area—from 25 cm2 to 100 cm2.

Improvements in multiple sign efficacy endpoints were observed in the full study population, with more pronounced effects in the TNFR1 genetic biomarker population.

A higher serum ferritin threshold could lead to better diagnosis and treatment of more women with iron deficiency.

This RAD 2024 interview featured a discussion of currently FDA-approved atopic dermatitis therapies and their comparisons.

Congly explains key findings from his cross-sectional study of costs associated with HBV treatment in patients on Medicaid and the economic impact of generic versus originator use.

This segment of Paller’s RAD 2024 interview covers tips for treating children with biologics as well as unmet needs of eczema patients and upcoming treatments.

An analysis of data from the NIH's All of Us program details the prevalence of fatigue among patients with pruritus among US patients.

The global, real-world TRACE study was designed to improve the understanding of tralokinumab’s safety, efficacy, and clinical utilization in daily practice for eczema.

In her RAD conference interview, Paller describes several treatments featured in her talk on the subject of pediatric eczema.

A real-world analysis of 60 patients suggests traolkinumab was effective in atopic dermatitis, regardless of prior therapy use.

In an interview at RAD 2024, Silverberg discusses ways to help patients navigate such comorbidities associated with eczema.

Phase 2 data presented at EASL showed 52 weeks of treatment with tirzepatide led to MASH resolution with no worsening of fibrosis in patients with MASH and F2/F3 fibrosis.

Lisa Swanson, MD, discusses the recent advancements in pediatric dermatology and emphasizes the importance of correctly diagnosing conditions to improve patient outcomes.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.

Knowledge, attitudes, and practices remain relevant for disease management among patients with anemia.

These data indicate the benefits of implementing individual protective measures in winter by patients with COPD.

During SLEEP 2024, Judite Blanc, PhD, discussed her team’s ongoing study assessing whether an education VR program improves maternal stress and sleep among women of color.

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

8 weeks of treatment with combination bemnifosbuvir and ruzasvir showed a 97% SVR rate at 12 weeks post-treatment in a phase 2 lead-in cohort.

At SLEEP 2024, Broussard told HCPLive about how eating time restriction can serve as another as another dietary tool for people who are unsuccessful with other strategies.

Broussard discussed the importance of eating during the day at SLEEP 2024.

High-impact chronic pain is a severely affected subgroup in SCD and is associated with greater pain burden and worse health outcomes.

These data suggest that those with psoriasis maintain an innate psychological vulnerability, indicating the necessity of addressing mental well-being in the disease’s management.

A study found that only 0.32% of 1.2 million patients underwent Lp(a) testing, with non-Hispanic Black and Hispanic patients significantly less likely to receive the test compared to White patients.

Survodutide, a glucagon/GLP-1 receptor dual agonist, improved MASH with no worsening of fibrosis, reduced liver fat content, and improved fibrosis by ≥ 1 stage in a phase 2 trial.

A lower FACIT-Fatigue score, indicating higher fatigue was independently associated with female sex, a high BMI, a high stress level, and poor sleep quality.